Molecular Profiling of Grade 3 Pancreatic Neuroendocrine Neoplasms (NEN) Reveals Frequent TP53 and CDKN2A Alterations in both NET and NEC

被引：0
|
作者：
Umetsu, Sarah [1 ]
Kakar, Sanjay [1 ]
Jones, Kirk [1 ]
Bergsland, Emily [1 ]
Kim, Grace [1 ]
Joseph, Nancy [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
MODERN PATHOLOGY | 2020年 / 33卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1792
引用
收藏
页码：1679 / 1680
页数：2
相关论文
共 13 条
  • [1] Molecular Profiling of Grade 3 Pancreatic Neuroendocrine Neoplasms (NEN) Reveals Frequent TP53 and CDKN2A Alterations in both NET and NEC
    Umetsu, Sarah
    Kakar, Sanjay
    Jones, Kirk
    Bergsland, Emily
    Kim, Grace
    Joseph, Nancy
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1679 - 1680
  • [2] Genetic Alterations of Both MEN1/ATRX and TP53/RB1 in Pancreatic Neuroendocrine Neoplasms
    Zhang, Ming-Yi
    He, Du
    Zhang, Shuang
    Liu, Ji-Yan
    PANCREAS, 2022, 51 (06) : e91 - e93
  • [3] TP53 mutations and CDKN2A mutations/deletions are highly recurrent molecular alterations in the malignant progression of sinonasal papillomas
    Brown, Noah A.
    Plouffe, Komal R.
    Yilmaz, Osman
    Weindorf, Steven C.
    Betz, Bryan L.
    Carey, Thomas E.
    Seethala, Raja R.
    McHugh, Jonathan B.
    Tomlins, Scott A.
    Udager, Aaron M.
    MODERN PATHOLOGY, 2021, 34 (06) : 1133 - 1142
  • [4] Targeted Genomic Profiling Reveals Highly Recurrent Molecular Alterations in the Malignant Progression of Sinonasal Papilloma to Sinonasal Squamous Cell Carcinoma, including CDKN2A Mutation/Deletion and TP53 Mutation
    Yilmaz, Osman
    Kunder, Komal
    McHugh, Jonathan
    Betz, Bryan L.
    Tomlins, Scott
    Brown, Noah
    Udager, Aaron M.
    LABORATORY INVESTIGATION, 2018, 98 : 492 - 492
  • [5] Targeted Genomic Profiling Reveals Highly Recurrent Molecular Alterations in the Malignant Progression of Sinonasal Papilloma to Sinonasal Squamous Cell Carcinoma, including CDKN2A Mutation/Deletion and TP53 Mutation
    Yilmaz, Osman
    Kunder, Komal
    McHugh, Jonathan
    Betz, Bryan L.
    Tomlins, Scott
    Brown, Noah
    Udager, Aaron M.
    MODERN PATHOLOGY, 2018, 31 : 492 - 492
  • [6] Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues
    Voutsadakis, Ioannis A.
    Digklia, Antonia
    CHINESE CLINICAL ONCOLOGY, 2023, 12 (01)
  • [7] Alterations in KRAS, CDKN2A, TP53, and SMAD4 Predict Disease-Free Survival in Resected Pancreatic Ductal Adenocarcinoma
    Morales-Oyarvide, V.
    Qian, Z.
    Rubinson, D. A.
    Nowak, J. A.
    Dunne, R. F.
    Kozak, M.
    Welch, M.
    Brais, L. K.
    Da Silva, A.
    Li, T.
    Li, W.
    Masuda, A.
    Yang, J.
    Shi, Y.
    Gu, M.
    Masugi, Y.
    Bui, J.
    Zellers, C.
    Yuan, C.
    Babic, A.
    Khalaf, N.
    Aguirre, A.
    Ng, K.
    Miksad, R.
    Bullock, A.
    Chang, D.
    Tseng, J.
    Clancy, T.
    Linehan, D.
    Findeis-Hosey, J.
    Doyle, L.
    Thorner, A.
    Ducar, M.
    Wollison, B.
    Laing, A.
    Hahn, W.
    Meyerson, M.
    Fuchs, C. S.
    Ogino, S.
    Hornick, J.
    Hezel, A.
    Koong, A.
    Wolpin, B. M.
    PANCREAS, 2017, 46 (10) : 1420 - 1421
  • [8] Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53
    Joseph, Nancy M.
    Umetsu, Sarah E.
    Kim, Grace E.
    Terry, Merryl
    Perry, Arie
    Bergsland, Emily
    Kakar, Sanjay
    ENDOCRINE PATHOLOGY, 2024,
  • [9] Mutation profiling in the PIK3CA, TP53, and CDKN2A genes in circulating free DNA and impalpable breast lesions
    Delmonico, Lucas
    Silva Magalhaes Costa, Mauricio Augusto
    Fournier, Marcia Vasconcellos
    Romano, Sergio de Oliveira
    do Nascimento, Cristina Moreira
    Barbosa, Andreia Soares
    Moreira, Aline dos Santos
    Scherrer, Luciano Rios
    Faria Ornellas, Maria Helena
    Alves, Gilda
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2019, 39 : 30 - 35
  • [10] Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.
    Ishii, N
    Maier, D
    Merlo, A
    Tada, M
    Sawamura, Y
    Diserens, AC
    Van Meir, EG
    BRAIN PATHOLOGY, 1999, 9 (03) : 469 - 479
12